急性細菌性皮膚・皮膚構造感染症市場：薬剤タイプ別、感染タイプ別、投与経路別、流通チャネル別、地域別

世界の急性細菌性皮膚・皮膚構造感染症市場は、2025年に40億7,340万米ドルと推定され、2032年には61億2,900万米ドルに達すると予測され、2025～2032年までの年間平均成長率（CAGR）は6.0%で成長すると予測されます。

図.急性細菌性皮膚・皮膚構造感染症市場シェア（%）、2025年地域別

急性細菌性皮膚・皮膚構造感染症（ABSSSI）とは、主要皮膚膿瘍、蜂巣炎、感染した創傷や潰瘍など、皮膚とその周辺組織や構造物を侵す一般的な細菌感染症を指します。ABSSSIを引き起こす一般的な細菌には、黄色ブドウ球菌（Staphylococcus aureus）や化膿レンサ球菌（Streptococcus pyogenes）などがあります。抗生物質耐性の上昇や、肥満、糖尿病、ライフスタイルの変化などの危険因子の増加により、ABSSSIの世界の発生率は増加しています。

市場力学

世界の高齢者の増加と糖尿病などの併存疾患の増加により、ABSSSIのリスクが高まっています。国際糖尿病連合によると、2020年には20～79歳の成人約4億6,300万人が糖尿病を患っており、この数字は2045年までに7億人以上に増加すると予測されています。高齢者は皮膚・軟部組織感染症にもかかりやすいです。急速な都市化と免疫の健康を損なうライフスタイルの変化が、ABSSSIの疾病負担を世界的にさらに増大させています。しかし、臨床検査や医薬品の承認に関する厳しい規制が市場の成長を阻害する可能性があります。新規抗菌薬の研究開発が進められており、先進的な創傷ケア療法が急速に普及しているため、市場には有利な機会がもたらされています。

本調査の主要特徴

• 当レポートでは、世界の急性細菌性皮膚・皮膚構造感染症市場を詳細に分析し、2024年を基準年とした予測期間（2025～2032年）の市場規模（100万米ドル）と複合年間成長率（CAGR%）を掲載しています。
• また、さまざまなセグメントにわたる潜在的な収益成長機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。
• また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域による展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
• 世界の急性細菌性皮膚・皮膚構造感染症市場における主要企業を、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいてプロファイルしています。
• 主要企業は、Fresenius SE &Co.KGaA、Pfizer, Inc.、Amneal Pharmaceuticals LLC、Intas Pharmaceuticals Ltd.、Cadila Healthcare Ltd.、Glenmark Pharmaceuticals Ltd.、GSK plc、Sun Pharmaceutical Industries Ltd.、Aurobindo Pharma Ltd.、AbbVie, Inc.、Melinta Therapeutics, Inc.、Accord Healthcare Ltd.、Merck &Co., Inc.、Teva Pharmaceutical Industries Ltd.、Paratek Pharmaceuticals, Inc.などです。
• 本レポートから洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
• 世界の急性細菌性皮膚・皮膚構造感染症市場は、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この産業の様々な利害関係者に対応しています。
• 利害関係者は、世界の急性細菌性皮膚・皮膚構造感染市場分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• 一貫型機会マップ（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• 影響分析
• 市場動向
• 規制シナリオ
• メーカー収益
• 非侵襲性センサ技術の採用
• 買収と提携のシナリオ
• 製品の発売/承認
• 資金調達と投資
• PEST分析
• ポーターの分析

第4章 世界の急性細菌性皮膚・皮膚構造感染症市場-コロナウイルス（COVID-19）パンデミックの影響

• 全体的な影響
• 政府の取り組み
• COVID-19による市場への影響

第5章 急性細菌性皮膚・皮膚構造感染症の世界市場、薬剤タイプ別、2020～2032年、（100万米ドル）

• イントロダクション
• 経口と非経口抗生物質
• オリタヴァンシン
• デラフロキサシン
• バンコマイシン
• その他
• 外用抗生物質
• 過酸化水素
• フシジン酸
• ムピロシン
• レタパムリン

第6章 世界の急性細菌性皮膚・皮膚構造感染症市場、感染タイプ別、2020～2032年、（100万米ドル）

• イントロダクション
• 院内感染ABSSSI
• コミュニティ獲得ABSSSI

第7章 急性細菌性皮膚・皮膚構造感染症の世界市場、投与経路別、2020～2032年、（100万米ドル）

• イントロダクション
• 経口
• 非経口
• 局所

第8章 世界の急性細菌性皮膚・皮膚構造感染症市場、流通チャネル別、2020～2032年、（100万米ドル）

• イントロダクション
• 病院薬局
• 小売薬局
• オンライン薬局

第9章 急性細菌性皮膚・皮膚構造感染症の世界市場、地域別、2020～2032年、（100万米ドル）

• イントロダクション
• 北米
• ラテンアメリカ
• 欧州
• アジア太平洋
• 中東
• アフリカ

第10章 競合情勢

• 企業プロファイル
  • Fresenius SE &Co. KGaA
  • Pfizer, Inc.
  • Amneal Pharmaceuticals LLC
  • Intas Pharmaceuticals Ltd.
  • Cadila Healthcare Ltd.
  • Glenmark Pharmaceuticals Ltd
  • GSK plc
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
  • AbbVie, Inc.
  • Melinta Therapeutics, Inc.
  • Accord Healthcare Ltd.
  • Merck &Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Paratek Pharmaceuticals, Inc.

第11章 アナリストの推奨事項

• 隆盛と衰退
• 一貫型機会マップ

第12章 参考文献と調査手法

• 参考文献
• 調査手法

Global Acute Bacterial Skin And Skin Structure Infections Market is estimated to be valued at USD 4,073.4 Mn in 2025 and is expected to reach USD 6,129.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.0% from 2025 to 2032.

Figure. Acute Bacterial Skin And Skin Structure Infections Market Share (%), By Region 2025

Acute bacterial skin and skin structure infections (ABSSSI) refer to common bacterial infections that involve the skin and surrounding tissue or structures such as major cutaneous abscesses, cellulitis, and infected wounds or ulcers. Some of the common bacteria that cause ABSSSI include Staphylococcus aureus and Streptococcus pyogenes. With rising antibiotic resistance and increasing risk factors such as obesity, diabetes, and lifestyle changes, the global incidence of ABSSSI increases.

Market Dynamics:

Growing geriatric population worldwide coupled with rising prevalence of comorbidities such as diabetes increases the risk of ABSSSI. According to the International Diabetes Federation, approximately 463 million adults aged 20-79 years lived with diabetes in 2020, and this figure is projected to rise to over 700 million by 2045. The elderly are also more susceptible to skin and soft tissue infections. Rapid urbanization and changes in lifestyle that compromise immune health have further increased the ABSSSI disease burden globally. However, stringent regulations pertaining to clinical trials and drug approvals can hinder the market growth. Ongoing R&D for novel antibacterial medications and rapid adoption of advanced wound care therapies offers lucrative opportunities in the market.

Key Features of the Study:

• This report provides an in-depth analysis of the global acute bacterial skin and skin structure infections market, and provides market size (USD Mn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global acute bacterial skin and skin structure infections market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GSK plc, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global acute bacterial skin and skin structure infections market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global acute bacterial skin and skin structure infections market.

Detailed Segmentation-

• By Drug Type:
  • Oral & Parenteral Antibiotics
  • Oritavancin
  • Delafloxacin
  • Vancomycin
  • Others
  • Topical Antibiotics
  • Hydrogen Peroxide
  • Fusidic Acid
  • Mupirocin
  • Retapamulin
• By Infection Type:
  • Hospital Acquired ABSSSI
  • Community Acquired ABSSSI
• By Route of Administration:
  • Oral
  • Parenteral
  • Topical
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Fresenius SE & Co. KGaA
  • Pfizer, Inc.
  • Amneal Pharmaceuticals LLC
  • Intas Pharmaceuticals Ltd.
  • Cadila Healthcare Ltd.
  • Glenmark Pharmaceuticals Ltd
  • GSK plc
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
  • AbbVie, Inc.
  • Melinta Therapeutics, Inc.
  • Accord Healthcare Ltd.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Paratek Pharmaceuticals, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Infection Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Adoption of Non-invasive Sensor Technologies
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Acute Bacterial Skin and Skin Structure Infections Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Acute Bacterial Skin and Skin Structure Infections Market, By Drug Type, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral & Parenteral Antibiotics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Oritavancin
• Delafloxacin
• Vancomycin
• Others
• Topical Antibiotics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Hydrogen Peroxide
• Fusidic Acid
• Mupirocin
• Retapamulin

6. Global Acute Bacterial Skin and Skin Structure Infections Market, By Infection Type, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Acquired ABSSSI
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Community Acquired ABSSSI
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Acute Bacterial Skin and Skin Structure Infections Market, By Route of Administration, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Parenteral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Topical
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Acute Bacterial Skin and Skin Structure Infections Market, By Distribution Channel, 2020 - 2032, (USD Mn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Acute Bacterial Skin and Skin Structure Infections Market, By Region, 2020 - 2032, (USD Mn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Infection Type, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Mn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • Fresenius SE & Co. KGaA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Pfizer, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Amneal Pharmaceuticals LLC
  • Intas Pharmaceuticals Ltd.
  • Cadila Healthcare Ltd.
  • Glenmark Pharmaceuticals Ltd
  • GSK plc
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Ltd.
  • AbbVie, Inc.
  • Melinta Therapeutics, Inc.
  • Accord Healthcare Ltd.
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Paratek Pharmaceuticals, Inc.

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact